Interesting...., looking through lists of others lucky enough to obtain the orphan grant and many have sponsors ( licensing deals)
Also news to me, it appears that, in previous deals made, big pharma have spent more on these specialised drugs than on greater population peers.
Again, well done PTX on putting the PTX-200 on the radar with the current AML study.
